Table 3.

Predictors of response at 6 and 12 months of treatment with abatacept in rheumatoid arthritis patients (multivariate analysis).

Response Variable	Independent Variable	B	Odds Ratio	p-Value (Variable)	95% Confidence INTERVAL	R2	Goodness of Fit
6 months
EULAR response
	Duration of previous BTs (months)	−0.026	0.97	0.004	0.95–0.99	R2 Cox Snell = 0.382 R2 Nagelkerke = 0.528	X2 = 10.396 p = 0.238
	PVAS	−0.052	0.95	0.003	0.91–0.98
	DAS28	−0.651	0.52	0.015	0.30–0.87
LDA
	DAS28	−0.367	0.69	0.032	0.49–0.96	R2 Cox Snell = 0.045 R2 Nagelkerke = 0.070	X2 = 7.062 p = 0.529
Remission
	Duration of ABA (months)	0.047	1.05	0.002	1.01–1.08	R2 Cox Snell = 0.349 R2 Nagelkerke = 0.581	X2 = 62.774 p < 0.001
	Concomitant glucocorticoids	1.993	7.34	0.031	1.33–54.79
	NPJ	−0.436	0.65	0.001	0.48–0.81
	ESR	−0.109	0.89	0.004	0.82–0.95
12 months
EULAR response
	PVAS	−0.069	0.93	<0.001	0.90–0.96	R2 Cox Snell = 0.335 R2 Nagelkerke = 0.447	X2 = 2.509 p = 0.961
	CTLA-4 rs5742909 (T vs. CC)	1.772	5.88	0.012	1.48–23.29
	CTLA-4 rs231775 (G vs. AA)	1.247	3.48	0.022	1.20–10.09
LDA
	CTLA-4 rs5742909 (T vs. CC)	1.556	4.75	0.016	1.35–17.94	R2 Cox Snell = 0.117 R2 Nagelkerke = 0.180	X2 = 0.156 p = 1
	CTLA-4 rs231775 (G vs. AA)	1.540	4.67	0.013	1.49–17.94
Remission
	Age at ABA start	−0.044	0.96	0.027	0.92–0.99	R2 Cox Snell = 0.239 R2 Nagelkerke = 0.339	X2 = 6.561 p = 0.585
	Number of previous BTs	−0.574	0.56	0.023	0.34–0.92
	PVAS	−0.051	0.95	<0.001	0.93–0.98

ABA, abatacept; BT, biological therapy; DAS28, 28-joints Disease Activity Score; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; LDA, low disease activity; NPJ, number of painful joints; PVAS, patient’s visual analogue scale.